INTRODUCTION
Antibody based photodynamic therapy, i.e. photoimmunotherapy (PIT), is an ideal modality to improve cancer treatment due to its selective and tumor specific mode of therapy. As the use of PIT for cancer treatment is continuing to be described, there is great need to characterize a standardized light source for PIT application. In this work, we designed and manufactured a Light Emitting Diode (LED) / PIT device and validated the technical feasibility, applicability, safety and consistency of the system for cancer treatment.
METHODS
To outline the characteristics and photo biological safety of the LED device multiple optical measurements were performed in accordance with the IEC62471 photo biological safety standard. A luciferase-transfected breast cancer cell line (2LMP-Luc) in combination with panitumumab-IRDye700DX (pan-IR700) was used to validate the in vitro and in vivo performance of our LED device.
RESULTS
Testing revealed the light source to be safe, easy-to-use, and independent of illumination and power output (mW cm 
CONCLUSION
To our knowledge, a normalized and standardized LED device has not been explicitly described nor developed. Here, we introduce a standardized light source and validate its usability for PIT applications.
INTRODUCTION
The ultimate goal of cancer treatment is obtaining complete removal of tumor tissue while minimizing damage to surrounding healthy tissue. 1, 2 Antibody based photodynamic therapy (PDT), i.e. photoimmunotherapy (PIT) can become an ideal modality to improve cancer treatment due to its inherent selectivity for targeting tumors. The application can be used for both initial treatment and eliminating residual (microscopic) disease during incomplete resection, which is common in pancreatic cancer (~75% positive margins) or locally advance rectal cancer (~35% positive margins). 3, 4 PIT employs a nontoxic light-sensitive compound (i.e. a photosensitizer) bound to a tumor-targeting antibody, which can serve as both a diagnostic and therapeutic agent. 5 A near-infrared (NIR) light-emitting diode (LED) is then used to excite the antibody-bound photosensitizer resulting in cell apoptosis and tumor ablation.
Numerous preclinical studies have described the therapeutic potential of PIT in multiple cancer types. [6] [7] [8] Its clinical relevance and application is mainly for superficial spreading cancers like skin cancer, melanoma, head and neck cancer, peritoneal metastases (ovarian or colorectal) or (microscopic) residual after an incomplete resection. However, the scientific standardization, performance, tuning, and validation of a light source for PIT has yet to be developed.
Over the past few years, the use of NIR high power LEDs for PIT applications has become more desirable due to the inexpensive and safe nature of the modality. 6 However, recent findings have shown that the performance can be compromised by illumination variations due to ineffective heat dissipation; especially considering the emitted peak wavelength is highly dependent upon the core temperature of the LED. 9 With an increase in core temperature, the emitted peak wavelength will be at a higher, less favorable wavelength for photosensitizer excitation of IRDye700DX, a commonly used preclinical PIT agent. 7, 10 The primary objective of this study was to design and manufacture a standardized, validated and safe Light Emitting Diode (LED) / photodynamic therapy (PDT) device for IRDye700DX based PIT cancer treatment. Our secondary objective was to provide a framework for standardization of in future studies, in which other new developed photosensitizers will be evaluated.
The key design parameters of the system developed were: To select a light source suitable for excitation of the IRDye700DX, illuminate a large field of view, obtain sufficient cooling to sustain light source within operating temperature, and achieve manageable power output levels (20 mW cm -2 -200 mW cm -2 ) for application in various in vitro and in vivo conditions. To 156 reach these functional specifications, a system, hereafter referred to as 'LED device' , was developed. The device was characterized using the standardized testing environment of domestic appliances, in vitro models, and in vivo xenograft mouse models of breast cancer.
MATERIALS & METHODS

SIMULATION AND NORMALIZATION
IRDye700DX (LiCor Biosciences) was utilized as the fluorescent photosensitizer. Illumination was provided by a 690nm (SMBB690D-1100-02) high output light-emitting diode (LED)
for fluorochrome excitation (Marubeni). The LED specifications are shown in Table 1 .
To ensure homogenous illumination of the area of interest to be photosensitized in the surgical field, predefined as 5 x 3 cm, with a power output ranging 20-200 mW cm -2 , a total of 126 individual LED bulbs were needed. To verify the design of the LED device, shown in Figure   1A , the optical design simulation tool 'LightTools' of Synopsys was used (Synopsys).
As demonstrated in Figure 1B , unlike power output, peak wavelength is highly dependent upon the LED temperature, therefore to assure optimal heat dissipation, 690nm high output LEDs (126 total) were mounted on Metal Core Printed Circuit Board (MCPCB) attached to the semiconductor-mounting surface of the heatsink (Fischer elektronik), after exact optical alignment. The special heat sink geometry, consisting of a hollow fin, optimizes the airflow for guaranteed effective heat dissipation, and as such will keep the temperature of the light sources within the operating temperatures to stabilize the peak wavelength. The LED system is provided with a tunable LED power supply module (HLG-240H-54B), which enables the user to adjust the emitted power output (mW cm -2 ) (Meanwell).
To outline the capabilities and photo biological safety of the LED device multiple optical mea- 
CELL LINE AND CULTURE
To validate the in vitro and in vivo performance of our LED system, 2LMP-Luc (a 2x lung metastatic pooled subclone of MDA-MB-231, a gift from Dr. Donald Buchsbaum, UAB), human breast carcinoma cell line was used. The 2LMP-Luc cells were previously transformed using the ViraPort retroviral vector (Stratagene). Cells were grown in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) in tissue culture flasks in a humidified incubated in an atmosphere of 37°C, 95% air and 5% carbon dioxide.
PANITUMUMAB-IRDYE700 CONJUGATION
The antibody used, panitumumab (Vectibix, Amgen; 177 kDa) is a fully humanized monoclonal antibody (mAb) directed specifically to the epidermal growth factor receptor (EGFR).
The photosensitizer IRDye700DX NHS ester (IR700; 2,0 kDa) was purchased from LI-COR Bioscience. Panitumumab was diluted to 5 mg mL -1 in PBS and incubated with the IR700 for 2 h at room temperature, according to manufacturer instruction. The mixture was purified with a desalting column (Pierce). After purification, the protein concentration and the number of dye molecules per protein were determined by absorption with UV-Vis spectroscopy (ThermoScientific). 
Figure 1 Schematic of LED device. (A) The LED device is provided with multiple LEDs (1) mounted on a cooling unit (2). The dimmer allows the user to adjust the power output to subject specifications (3). (B)
The cooling unit is used to stabilize peak wavelength.
158
In order to determine in vitro immunoreactivity of the panitumumab-IR700 (pan-IR700) after conjugation, a binding assay was performed. Briefly, 3.0x105 cells were resuspended in phosphate buffer solution (PBS) containing 5% FBS. Pan-IR700 was added (10 μg mL 
IN VITRO CELL VIABILITY ASSAY
To assess PIT effects using the LED device in vitro, cells were harvested and seeded into two 24 well, black welled plates (Wallac) at 2. 
STATISTICAL ANALYSIS
Data are expressed as means ± s.e.m. from triplicate experiments, unless otherwise indicated.
Independent-and paired samples T-tests were used to compare treatment effect with that of control. For statistical analysis, SPSS version 21.0 was used. P < 0.05 was considered to indicate a statistically significant difference.
RESULTS
SYSTEM CHARACTERIZATION
After placing a receiver at various distances from the light source the peak and average light intensities were simulated (Synopsys). Figure 2A demonstrates that at a distance of 20 cm on an area of 5 x 3 cm both the peak and average power output were 200 mW cm -2 . Furthermore, the simulation shows an equal energy distribution (Fig. 2B) at the predefined area of interest (5 x 3 cm), making this device suitable for in vitro and in vivo applications of PIT. Moreover the special heat sink geometry was able to keep the temperature within the necessary operating temperature of 50°C (Fig. 2C ) to stabilize the peak wavelength over time (Fig. 2D) .
To verify the optical design and safety of the LED device, a series of system and safety characterizations was performed. LED system specifications are shown in Table 1 . The measured maximum light output was concordant with the simulation and was determined to be 206 mW cm -2 , with the detector at a distance of 20 cm of the light source. As demonstrated in Table 2 , there was no potential hazard concerning the eye or skin to disclose. The EHV for retinal thermal-and thermal skin injury were respectively at 34% and 49% of the emission limit for exempt. Moreover, the EHV for potential hazard caused by infrared exposure to the eye was below the measuring capability range of the used system, and therefore far below the emission limit for exempt. ) induced a significantly higher percentage of cell death (32.4% ± 1.4%; 68.5% ± 1.5%; 89.2% ± 2.4% respectively) in comparison to untreated control cells (5.7% ± 1.0%: P < 0.001). We did not observe significant cytotoxicity without pan-IR700 due to light exposure of 2 J cm -2 (5.3% ± 1.0%), 4 J cm -2 (3.9% ± 0.5%), and 6 J cm -2 (5.3% ± 0.6%). Treatment with pan-IR700 in absence of light from the LED device induced no significant cytotoxicity (9.9% ± 0.2%) relative to the PIT treated groups.
To confirm binding-specific pan-IR700 mediated phototoxicity, 2LMP-Luc cells were incubated with an excess of unlabeled panitumumab to saturate the EGFR target antigen, prior to incubating the cells with the pan-IR700 conjugate (10 μg mL -1 ) and exposure to light of the LED device. Blocking the EGFR antigen-binding site significantly (P < 0.001) reduced the percentage of cytotoxicity at PIT energy of 2 J cm -2 (9.6% ± 0.9%), 4 J cm -2 (11.3% ± 0.8%) and 6 J cm -2 (11.8% ± 0.9%) after LED illumination. Microscopy studies directly following a 6 J cm -2 treatment dose revealed cellular bleb formation and swelling, which are indicators of necrotic cell death induced by PIT (Fig. 3C ). 
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DISCUSSION
The use of PIT for treatment of solid tumors is highly relevant for either superficially located cancer types (primary tumor and locoregional metastases) such as skin cancer, melanoma, head and neck cancer, or colorectal or ovarian peritoneal metastases and also for treatment of (microscopic) residual disease after an incomplete microscopic R1 resection or macroscopic R2 resection. As PIT advances rapidly from pre-clinical validation towards clinical use, there is great need for a standardized light source to be introduced. A viable candidate for FDA-consideration will be safe, cheap, easy-to-build, robust, reliable, and independent of (illumination) and temperature variations. To our knowledge, a normalized and standardized LED device has never been explicitly described, developed, or validated.
We developed a device appropriate for IR700 excitation that is safe, universal and standardized. While high output laser devices are getting cheaper with costs ranging from $10,000 to $25,000, we were able to build a cost friendly and easy to build LED (prototype) device for less than $1,500. We anticipate that in next generation build devices this will be even cheaper due to reduction in costs of manufacturing larger quantities of components such as LEDs and electronic constituents.
Light in the NIR suffers from little attenuation, with penetration depth up to 1 cm.
12 Therefore the skin and eyes of the human body are most at risk when exposed to optical radiation.
Although these hazards have been recognized for laser light for many years, its implication in LED light is relatively new, though necessary since the introduction of high-power LEDs. 13 Hazard test confirmed that there were no potential hazards concerning the eye or skin to disclose for the device as tested. Moreover, we found that the multiple LEDs mounted on heat exchanger guarantees optimal thermal management of the LEDs, permitting the device to remain within its operating temperatures to deliver consistent peak wavelength at IR700 optimal peak excitation wavelength (nm).
Consistent with literature, we show that target-specific killing by the LED device was achieved in response to a single dose of pan-IR700 and PIT for both in vitro and in vivo studies. [5] [6] [7] Pan-IR700 localized specifically in EGFR-positive 2LMP-Luc tumors as determined by non-invasive optical imaging. This study demonstrates furthermore, that target-selective accumulation of pan-IR700 in the EGFR-positive 2LMP-Luc tumors was dose dependent. In vivo decrease in tumor growth was confirmed after one dose of 0.3 mg pan-IR700 followed by one single bolus exposure to light from the LED device (50 J cm -2 ).
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Numerous reports have been published about the clinical implications of fluorescence imaging, providing the surgeon with real time visualization of tumors deposits in order to improve resection rates and thus positively influence prognosis. Nevertheless, due to anatomical restraints such as vital tissues, the risk of minimal residual disease remains after an incomplete microscopic resection (R1 resection) or even a macroscopic irradical resection (R2 resection).
PIT can provide clinical applicability not solely for superficial spreading tumors but also as an adjuvant treatment modality after surgery for irradiating the remaining tumor cavity and its in situ resection margins. We envision the application used for treatment of localized disease, such as in peritoneal metastases, with a hand-held device or in an outpatient clinic setting, such as treatment for superficial cutaneous metastases. A highly advantageous feature of the IR700 photosensitizer is that upon excitation it also generates fluorescence. Extending our LED device with a specialized camera system (sensitive charge-coupled device: CCD) enables simultaneous registration and processing of the signal for intraoperative real-time imaging purposes combined with PIT capabilities. Moreover making several technical adjustments may optimize the efficacy of our LED device even more. For example, the bandwidth of the LED presented here is 20nm. Including additional cut-off filters or selecting LEDs with a narrower bandwidth may be able to increase specificity. Moreover further research is necessary to evaluate whether employing a pulse controller will increase the efficacy of our LED device.
We envision that PIT allows for delineation of tumor margins through optical imaging, and subsequent light based phototherapy to eliminate residual microscopic disease thereby aiding the surgeon in obtaining a more radical resection while preserving as much as possible functionality with minimal collateral damage.
CONCLUSION
To our knowledge, a normalized and standardized LED device has not been explicitly described nor developed. Here, we introduced a standardized light source and validated its usability for PIT applications.
